TLR2 and cancer: TLR2L-800 has high TLR2-binding affinity (11 nmol/L Ki) and high agonist activity (34 nmol/L EC50), and unconjugated TLR2L alone was shown to have potential for use as an immune adjuvant for cancer immunotherapy (26).